These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 9179227

  • 1. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.
    Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
    [Abstract] [Full Text] [Related]

  • 2. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.
    Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ, Zhong GR, Salako Q, Li M, DeNardo GL, Meares CF.
    J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
    [Abstract] [Full Text] [Related]

  • 4. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
    DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL.
    J Nucl Med; 1998 May; 39(5):842-9. PubMed ID: 9591587
    [Abstract] [Full Text] [Related]

  • 5. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA.
    Cancer Res; 1992 Feb 15; 52(4):904-11. PubMed ID: 1737353
    [Abstract] [Full Text] [Related]

  • 6. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL.
    Clin Cancer Res; 2005 Aug 15; 11(16):5920-7. PubMed ID: 16115934
    [Abstract] [Full Text] [Related]

  • 7. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL.
    Cancer Biother Radiopharm; 1999 Oct 15; 14(5):381-95. PubMed ID: 10850323
    [Abstract] [Full Text] [Related]

  • 8. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ.
    J Nucl Med; 2000 May 15; 41(5):952-8. PubMed ID: 10809213
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec 15; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

  • 11. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec 15; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 12. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
    Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA, Ceriani RL.
    Clin Cancer Res; 1998 Jul 15; 4(7):1679-88. PubMed ID: 9676842
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, Esteban JM, Neumaier M, Dresse S, Wu AM, Primus FJ, Shively JE, Raubitschek AA.
    J Nucl Med; 1997 Dec 15; 38(12):1951-9. PubMed ID: 9430476
    [Abstract] [Full Text] [Related]

  • 14. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
    Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1192-8. PubMed ID: 16965873
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ.
    J Nucl Med; 2005 Apr 15; 46(4):634-41. PubMed ID: 15809486
    [Abstract] [Full Text] [Related]

  • 16. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [Abstract] [Full Text] [Related]

  • 17. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
    DeNardo SJ, Gumerlock PH, Winthrop MD, Mack PC, Chi SG, Lamborn KR, Shen S, Miers LA, deVere White RW, DeNardo GL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
    [Abstract] [Full Text] [Related]

  • 18. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
    DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL.
    J Nucl Med; 1997 Aug 01; 38(8):1180-5. PubMed ID: 9255145
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.
    Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, Frincke JM, Lollo CP, Larson SM, Carrasquillo JA.
    Clin Cancer Res; 1998 Nov 01; 4(11):2691-700. PubMed ID: 9829731
    [Abstract] [Full Text] [Related]

  • 20. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.